Genetic and genomic progressions in breast cancer
DOI:
https://doi.org/10.47464/MetroCiencia/vol30/2/2022/88-91Keywords:
breast cancer, BRCA1, BRCA2Abstract
The review article "Genetic and genomic progress in breast cancer" describes the most relevant findings on the genetics of breast cancer, from the description of the disease, predictive genetic tests, affected genes and a mention of the recommended surgical treatment . In the same way, the approach and clinical advice require an additional focus in decision making for daily practice, especially for patients with BRCA1/2 involvement.
Downloads
References
Wang F, Fang Q, Ge Z, Yu N, Xu S, Fan X. Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review. Mol Biol Rep [Internet]. 2012 Mar [cited 2022 Jun 7];39(3):2109–18. Available from: https://pubmed.ncbi.nlm.nih.gov/21643751/
Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA - J Am Med Assoc. 2018 Jun 19;319(23):2401–9.
Syngal S, Furniss CS. Germline Genetic Testing for Pancreatic Ductal Adenocarcinoma at Time of Diagnosis. JAMA [Internet]. 2018 Jun 19 [cited 2022 Jun 7];319(23):2383–5. Available from: https://pubmed.ncbi.nlm.nih.gov/29922810/
Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol [Internet]. 2007 Apr 10 [cited 2022 Jun 7];25(11):1329–33. Available from: https://pubmed.ncbi.nlm.nih.gov/17416853/
Weitzel JN, Clague J, Martir-Negron A, Ogaz R, Herzog J, Ricker C, et al. Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol [Internet]. 2013 Jan 10 [cited 2022 Jun 7];31(2):210–6. Available from: https://pubmed.ncbi.nlm.nih.gov/23233716/
Judkins T, Rosenthal E, Arnell C, Lynn ;, Burbidge A, Geary W, et al. Clinical Significance of Large Rearrangements in BRCA1 and BRCA2. Available from: https://www.myriadpro.com/BRAC_BART
Friebel TM, Domchek SM, Rebbeck TR, Rebbeck T. Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis. 2014; Available from: https://academic.oup.com/jnci/article/106/6/dju091/2606840
Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, et al. Effectiveness of Alternating Mammography and Magnetic Resonance Imaging for Screening Women With Deleterious BRCA Mutations at High Risk of Breast Cancer.
WP T, C L, A E, K M, S B, M B, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol [Internet]. 2020 Oct 1 [cited 2022 Jun 7];38(30):647–55. Available from: https://pubmed.ncbi.nlm.nih.gov/32790492/
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Vanessa Romero
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
